通讯作者: 陈曦, fuzhoucxi@163.com

DOI：10.12201/bmr.202511.00037

The Research Progress of Traditional Chinese Medicine Monomers in Precancerous Lesions of Gastric Cancer

• 摘要：胃癌前病变(precancerous lesions of gastric cancer, PLGC)是胃黏膜由慢性炎症向腺癌演进的关键病理阶段,涵盖肠上皮化生及各级别异型增生。根除幽门螺杆菌虽可降低胃癌风险,但对已形成的分子事件缺乏有效干预。中药单体因其结构明确、质量可控、多靶点作用,近五年在PLGC防治中取得重要进展。本文系统检索PubMed、Web of Science、CNKI、万方2020-01-01至2025-05-31的中英文文献,围绕“炎症-增殖-信号通路”三大核心机制,对人参皂苷Rb1、黄芪甲苷、汉防己乙素等代表性单体的体内外证据进行循证评价,以期为PLGC精准防治提供新思路。

  关键词： 胃癌前病变; 中药单体; 人参皂苷Rb1; 黄芪甲苷; 循证医学

   

  Abstract: Precancerous lesions of gastric cancer represent a critical pathological stage in the progression from chronic gastritis to adenocarcinoma, encompassing intestinal metaplasia (IM) and dysplasia of various grades. Although eradication of Helicobacter pylori can reduce the risk of gastric cancer, it lacks effective intervention for the molecular events that have already occurred. Traditional Chinese medicine monomers, with their well-defined structures, controllable quality, and multi-target actions, have made significant progress in the prevention and treatment of PLGC in the past five years. This article systematically reviewed the Chinese and English literature from PubMed, Web of Science, CNKI, and Wanfang databases from January 1, 2020, to May 31, 2025.Focusing on the three core mechanisms of “inflammation-proliferation-signal transduction pathways,” we evaluated the in vitro and in vivo evidence of representative monomers such as ginsenoside Rb1, astragaloside IV, and tetrandrine through evidence-based assessment, aiming to provide new insights for the precise prevention and treatment of PLGC.

  Key words: Gastric precancerous lesions; Traditional Chinese medicine monomers; Ginsenoside Rb1; Astragaloside IV; Evidence-based medicine

  提交时间：2025-11-17

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 程悦, 郝小鹰. 胃泌素在胃癌前病变中的临床研究进展. 2025. doi: 10.12201/bmr.202502.00030

  胡张琴, 李东芳. 基于“瘀-毒-虚”理论治疗老年性胃癌的经验. 2025. doi: 10.12201/bmr.202509.00069

  郝雅琴, 胡云峰, 郝静, 赵鑫. 环状RNA与自噬在胃癌中作用的研究进展. 2023. doi: 10.12201/bmr.202304.00001

  庄旭颉, 高丽丽. 基于NLRP3信号通路探究中医药靶治疗缺血性脑卒中的研究进展. 2025. doi: 10.12201/bmr.202509.00056

  王耀强, 汪浩浩, 罗长江. HMGB1在胃癌进展和治疗中的作用. 2024. doi: 10.12201/bmr.202412.00009

  朱林, 蒋涛. 中医药调控相关信号通路治疗膝骨关节炎的研究进展. 2025. doi: 10.12201/bmr.202509.00021

  付涛涛, 陈艳梅, 李庆娜, 邵义明, 苏国彬, 弓孟春. 基于《中国药典》的中药知识图谱的构建与应用. 2024. doi: 10.12201/bmr.202407.00039

  文智琦, 陈继东. 基于国家专利复方治疗桥本甲状腺炎的中药配伍规律研究. 2025. doi: 10.12201/bmr.202508.00015

  王国超, 金敏, 通信作者:金敏. 逆转细菌耐药性中药及其作用机制研究进展. 2025. doi: 10.12201/bmr.202503.00056

  王亚楠, 王欢, 马莹, 田婧楠, 卢义. 免疫检查点抑制剂相关性甲状腺功能减退的中西医诊疗进展. 2025. doi: 10.12201/bmr.202505.00004

• 序号	提交日期	编号	操作
  1	2025-10-29	10.12201/bmr.202511.00037V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论